Pharmasum Therapeutics

Pharmasum Therapeutics is a preclinical-stage biotech targeting dementia, one of the largest unmet medical needs, through inhibition of the DYRK1A kinase. Its lead candidate, PST-674, is a small molecule developed using advanced drug design and X-ray crystallography, with a strategic clinical entry point in Down syndrome-associated dementia due to a strong genetic rationale. The company, operating from Norway and the UK, plans to conduct a PoC study before partnering for Phase 3 development, aiming to capture value in a projected $40 billion global dementia therapy market by 2030.

Small-molecule drug discovery platform focused on designing proprietary inhibitors of the DYRK1A kinase, utilizing X-ray crystallography and Structure-Activity Relationship (SAR) studies for lead optimization.

The dementia therapeutic space is highly competitive and rapidly evolving, with recent approvals of anti-amyloid antibodies (e.g., lecanemab) setting a new benchmark. Pharmasum competes with numerous companies targeting tau, neuroinflammation, and other pathways. Its differentiation lies in the novel DYRK1A target and its strategic clinical development path starting in Down syndrome.